Michael Barbella, Managing Editor02.08.23
OssDsign AB has released a new size of OssDsign Catalyst to the U.S. market.
The additional volume option of 1 cubic centimetre (cc) completes the existing product range of 10cc, 5cc and 2.5cc, and broadens access to new procedures in both cervical spine and smaller extremities. “We are excited to announce that our new smaller size of OssDsign Catalyst is now available in the U.S. We see a rapidly growing interest in our innovative nanosynthetic bone graft, and by this extension of the Catalyst product range, more patients can be helped. For OssDsign this means that we can further increase our commercial opportunity,” OssDsign CEO Morten Henneveld said.
The 1cc option addition completes the OssDsign Catalyst size range, giving the company competitive strength in hospital approval processes and allowing for deeper usage in already approved hospitals. The 1cc size also allows the company to target ambulatory surgery centers (ASCs), which engage a large number of surgeons from different hospitals, thereby increasing product awareness among a broader surgeon population.
“We are very happy to extend our offering and further increase our commercial opportunity, as our new smaller size of OssDsign Catalyst gives access to additional procedures. It also means we can now offer a complete and more competitive size range to both existing users and new potential hospitals,” Henneveld noted.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body.
OssDsign develops next-generation bone replacement products that support the body’s own healing capabilities, thereby improving the clinical outcome in various orthopedic areas. Its product portfolio consists of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
The additional volume option of 1 cubic centimetre (cc) completes the existing product range of 10cc, 5cc and 2.5cc, and broadens access to new procedures in both cervical spine and smaller extremities. “We are excited to announce that our new smaller size of OssDsign Catalyst is now available in the U.S. We see a rapidly growing interest in our innovative nanosynthetic bone graft, and by this extension of the Catalyst product range, more patients can be helped. For OssDsign this means that we can further increase our commercial opportunity,” OssDsign CEO Morten Henneveld said.
The 1cc option addition completes the OssDsign Catalyst size range, giving the company competitive strength in hospital approval processes and allowing for deeper usage in already approved hospitals. The 1cc size also allows the company to target ambulatory surgery centers (ASCs), which engage a large number of surgeons from different hospitals, thereby increasing product awareness among a broader surgeon population.
“We are very happy to extend our offering and further increase our commercial opportunity, as our new smaller size of OssDsign Catalyst gives access to additional procedures. It also means we can now offer a complete and more competitive size range to both existing users and new potential hospitals,” Henneveld noted.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body.
OssDsign develops next-generation bone replacement products that support the body’s own healing capabilities, thereby improving the clinical outcome in various orthopedic areas. Its product portfolio consists of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.